Ng Benjamin, Kolli Hema, Ajith Kumar Naduviledeth, Azzopardi Matthew, Logeswaran Abison, Buensalido Julius, Mushtaq Bushra, Chavan Randhir, Chong Yu Jeat
Birmingham and Midland Eye Centre, Dudley Road, Birmingham B18 7QH, UK.
Christ Church, University of Oxford, St. Aldate's, Oxford OX1 1DP, UK.
Life (Basel). 2024 Jan 29;14(2):193. doi: 10.3390/life14020193.
Faricimab is a newly approved bispecific antibody for neovascular age-related macular degeneration (nAMD). Our study aims to evaluate clinical outcomes of faricimab switching in patients with treatment-refractory nAMD; determine parameters that predict these outcomes; and obtain patient subjective experience on this new injection. This is a retrospective case review with clinical and imaging data from a tertiary referral unit (Birmingham and Midland Eye Centre, UK), involving patients who were switched to faricimab between 1 January and 1 December 2023. In all, 63 eyes (54 patients) with a mean age of 79.2 ± 7.8 and mean of 41.5 ± 22.4 previous anti-VEGF injections were analysed. With a mean of 4.81 ± 1.16 faricimab injections over 6.98 ± 1.75 months, post-treatment visual acuity was logMAR 0.49 ± 0.36 and central macular thickness (CMT) was 320.3 ± 97.9 µm. After first dose, 39.1% achieved complete dryness and 89.1% had anatomical improvement. Presence of subretinal fluid was a predictor of better functional outcomes ( = 0.001, β = -0.182), while initial CMT predicted better anatomical outcomes ( = 0.001, β = 0.688). Compared to their experiences of previous anti-VEGF injections, 89% of patients reported no more discomfort and 87.0% experienced no more floaters, photopsia, or bubbles post-injection. Faricimab switching has anatomical efficacy but limited functional improvement in treatment-refractory AMD. Patient experiences of faricimab compared to previous injections were overall positive.
法瑞西单抗是一种新获批用于治疗新生血管性年龄相关性黄斑变性（nAMD）的双特异性抗体。我们的研究旨在评估法瑞西单抗转换治疗难治性nAMD患者的临床结局；确定预测这些结局的参数；并获取患者对这种新注射剂的主观体验。这是一项回顾性病例研究，使用了来自一家三级转诊单位（英国伯明翰和中部眼科中心）的临床和影像数据，研究对象为2023年1月1日至12月1日期间转换为使用法瑞西单抗治疗的患者。共分析了63只眼（54例患者），平均年龄为79.2±7.8岁，之前平均接受过41.5±22.4次抗血管内皮生长因子（VEGF）注射。在6.98±1.75个月内平均注射4.81±1.16次法瑞西单抗后，治疗后的视力为LogMAR 0.49±0.36，中心黄斑厚度（CMT）为320.3±97.9µm。首次注射后，39.1%的患者实现了完全干燥，89.1%的患者有解剖学改善。视网膜下液的存在是功能结局更好的预测因素（P = 0.001，β = -0.182），而初始CMT预测解剖学结局更好（P = 0.001，β = 0.688）。与之前抗VEGF注射的体验相比，89%的患者报告不再有不适感，87.
